Nov 19, 2010 ˇ The Thalidomide-Dexamethasone (TD) regimen has provided encouraging results in relapsed MM. To improve results, bortezomib (Velcade) has ...
Inclusion criteria: patients in first progression or relapse after at least one autologous transplantation, including those who had received bortezomib or ...
People also ask
What is the difference between Velcade and bortezomib?
Why is dexamethasone given with bortezomib?
What does Velcade do for multiple myeloma?
What is bortezomib thalidomide dexamethasone regimen?
3043 Introduction The Thalidomide-Dexamethasone (TD) regimen has provided encouraging results in relapsed MM. To improve results, bortezomib (Velcade) has ...
Bortezomib (Velcade (R))-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing ...
Bortezomib (velcade)-thalidomide-dexamethasone (VTD) is superior ...
www.muni.cz › Vũzkum › Publikace
Bortezomib (velcade)-thalidomide-dexamethasone (VTD) is superior to thalidomide-dexamethasone (TD) in patients with multiple myeloma (MM) progressing or ...
Bortezomib combined with thalidomide and dexamethasone was better than either bortezomib monotherapy or thalidomide with dexamethasone (p < 0.001). In ...
For example, bortezomib, thalidomide, dexamethasone (VTD) has particular value in renal failure since none of the drugs need dose modification. Similarly, the ...
In the 2005-01 trial, we have demonstrated that bortezomib-dexamethasone as induction therapy before autologous stem cell transplantation was superior to ...
Mar 2, 2011 ˇ ... in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). Patients and Methods.
Combinations of bortezomib, thalidomide, and lenalidomide with conventional agents or among each other have resulted in enhanced response rates and efficacy.